Remove 2020 Remove Leads Remove Side effects
article thumbnail

Influencer marketing in pharma

World of DTC Marketing

bil­lion in 2020, ac­cord­ing to In­flu­encer Mar­ket­ing Hub , which es­ti­mat­ed the mar­ket would grow to $13.8 At the same time, over­all dig­i­tal ad spend in the phar­ma space sky­rock­et­ed 242% year over year from Jan­u­ary to Feb­ru­ary in 2020 and 2021, Me­di­aRadar re­port­ed. bil­lion in 2021.

Marketing 192
article thumbnail

First nasal monoclonal antibody COVID-19 treatment shows potential

European Pharmaceutical Review

We discovered a way to shut down inflammation… in a patient with multiple sclerosis as well as in healthy patients,” stated lead author Thais Moreira, PhD, an assistant scientist at the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital and an instructor in Neurology at Harvard Medical School.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.

article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

This is especially beneficial as a way of decreasing potential side effects. In the years 2015 and 2020, clinical-stage cancer programmes increased by a considerable 77 percent (1,642 to 2,911), resulting in a quarter of drugs currently in development worldwide being highly potent.

article thumbnail

Santhera seeks speedy FDA review of Duchenne drug vamorolone

pharmaphorum

The Swiss biotech is seeking a priority review for vamorolone, which was licensed from US biotech ReveraGen BioPharma in 2020 after Santhera its former DMD therapy candidate idebenone failed clinical testing and was abandoned. Its lead drug has already claimed fast track and rare paediatric disease designations from the FDA.

FDA 98
article thumbnail

Sanofi looks east with €300m Innovent cancer alliance

pharmaphorum

SAR444245, meanwhile, is a long-acting IL-2 that blocks off part of the molecule that engages with alpha receptors, designed to maintain the anticancer efficacy of the molecule while preventing side effects. It is being tested in a wide range of solid tumours and lymphoma, alone and in combination with other drugs.

article thumbnail

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

pharmaphorum

It is a challenging proposition, however, as delivery of the therapeutic gene sequences to cells can be difficult and raises the risk of insertion mutations that can lead to side effects, including cancer. billion agreement that started in 2020.